Index - P/E - EPS (ttm) - Insider Own 59.23% Shs Outstand 19.51M Perf Week 1.40%
Market Cap 212.66M Forward P/E - EPS next Y - Insider Trans 127.77% Shs Float 4.93M Perf Month -
Income - PEG - EPS next Q - Inst Own - Short Float - Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans - Short Ratio - Perf Half Y -
Book/sh - P/B - EPS next Y - ROA - Short Interest - Perf Year -
Cash/sh - P/C - EPS next 5Y - ROE - 52W Range 9.40 - 12.30 Perf YTD 1.68%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -11.38% Beta -
Dividend TTM - Quick Ratio - Sales past 5Y 0.00% Gross Margin - 52W Low 16.02% ATR (14) 1.53
Dividend Ex-Date - Current Ratio - EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility 14.46% -
Employees 58 Debt/Eq - Sales Y/Y TTM - Profit Margin - Recom - Target Price -
Option/Short No / Yes LT Debt/Eq - EPS Q/Q - Payout - Rel Volume 0.43 Prev Close 10.90
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings - Avg Volume 240.05K Price 10.90
SMA20 1.63% SMA50 1.63% SMA200 1.63% Trades
Volume 103,870 Change 0.00%
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Northpond Ventures II GP, LLC 10% Owner Oct 15 '24 Buy 11.00 763,636 8,399,996 763,636 Oct 17 06:34 PM AH Equity Partners Bio I, L.L. 10% Owner Oct 15 '24 Buy 11.00 727,272 7,999,992 1,579,885 Oct 17 05:05 PM Enavate Sciences GP, LLC 10% Owner Oct 15 '24 Buy 11.00 1,363,636 14,999,996 3,785,802 Oct 17 04:15 PM Polaris Management Co. VII, L. 10% Owner Oct 15 '24 Buy 11.00 909,090 9,999,990 909,090 Oct 15 06:00 PM 5AM Partners VI, LLC 10% Owner Oct 15 '24 Buy 11.00 909,090 9,999,990 2,625,145 Oct 15 05:56 PM Nashat Amir Director Oct 15 '24 Buy 11.00 909,090 9,999,990 909,090 Oct 15 05:49 PM Schwab Andrew J. Director Oct 15 '24 Buy 11.00 909,090 9,999,990 2,625,145 Oct 15 05:48 PM Cohenour Jason Director Jun 05 '24 Sale 0.83 8,640 7,176 0 Jun 06 09:00 AM Cohenour Jason Director Mar 05 '24 Option Exercise 0.00 7,824 0 10,962 Mar 07 07:41 PM Scott Richard M. Chief Legal Officer, Secretary Nov 05 '23 Option Exercise 0.00 3,167 0 53,090 Nov 07 02:48 PM
Index - P/E - EPS (ttm) - Insider Own - Shs Outstand 38.32M Perf Week 30.09%
Market Cap 1.02B Forward P/E - EPS next Y - Insider Trans - Shs Float 20.23M Perf Month 38.14%
Income - PEG - EPS next Q -7.23 Inst Own 10.05% Short Float 1.14% Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans 179.72% Short Ratio 1.09 Perf Half Y -
Book/sh -7.54 P/B - EPS next Y - ROA - Short Interest 0.23M Perf Year -
Cash/sh 4.62 P/C 5.56 EPS next 5Y - ROE - 52W Range 16.17 - 23.50 Perf YTD 41.49%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High 9.28% Beta -
Dividend TTM - Quick Ratio 4.82 Sales past 5Y - Gross Margin - 52W Low 58.81% ATR (14) 1.96
Dividend Ex-Date Dec 24, 2019 Current Ratio 4.82 EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility 10.29% 11.15%
Employees - Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 36.75
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q - Payout - Rel Volume 1.25 Prev Close 23.23
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings Aug 28 Avg Volume 212.48K Price 25.68
SMA20 34.97% SMA50 36.56% SMA200 36.56% Trades
Volume 265,193 Change 10.55%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-08-24 Initiated Morgan Stanley
Overweight
$40
Oct-08-24 Initiated Jefferies
Buy
$35
Oct-08-24 Initiated Guggenheim
Buy
$45
Oct-08-24 Initiated Citigroup
Buy
$27
Oct-14-24 06:45AM
Sep-19-24 04:15PM
Sep-13-24 04:09PM
12:19AM
Sep-12-24 10:37PM
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MOULDER LEON O JR Chief Executive Officer Sep 18 '24 Buy 17.91 10,000 179,100 1,662,039 Sep 20 06:34 PM MOULDER LEON O JR Chief Executive Officer Sep 20 '24 Buy 18.45 5,000 92,270 1,672,039 Sep 20 06:34 PM MOULDER LEON O JR Chief Executive Officer Sep 19 '24 Buy 17.89 5,000 89,450 1,667,039 Sep 20 06:34 PM Enavate Sciences GP, LLC 10% Owner Sep 16 '24 Buy 17.00 882,353 15,000,001 3,761,359 Sep 18 04:15 PM Lu Hongbo Director Sep 13 '24 Buy 17.00 58,823 999,991 58,823 Sep 17 07:52 PM ENRIGHT PATRICK G Director Sep 16 '24 Buy 17.00 440,000 7,480,000 774,530 Sep 16 08:57 PM Nunn Jason Raleigh Director Sep 16 '24 Buy 17.00 882,352 14,999,984 1,946,564 Sep 16 08:54 PM Fairmount Funds Management LLC Director Sep 16 '24 Buy 17.00 300,000 5,100,000 1,604,891 Sep 16 08:54 PM SR ONE CAPITAL MANAGEMENT, LLC 10% Owner Sep 16 '24 Buy 17.00 2,235,294 37,999,998 1,946,564 Sep 16 08:51 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
